

Resource Summary Report

Generated by [dkNET](#) on Jul 29, 2026

CD8

RRID:AB_2075537

Type: Antibody

Proper Citation

Agilent Cat# M7103, RRID:AB_2075537

Antibody Information

URL: http://antibodyregistry.org/AB_2075537

Proper Citation: Agilent Cat# M7103, RRID:AB_2075537

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Used By NYUIHC-16. Original Manufacturer: Dako. Now part of Agilent. Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: CD8

Description: This monoclonal targets CD8

Target Organism: human

Clone ID: C8/144B

Antibody ID: AB_2075537

Vendor: Agilent

Catalog Number: M7103

Record Creation Time: 20250820T042357+0000

Record Last Update: 20250820T185205+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 77 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Yu KKH, et al. (2026) Characterization of a pathogenic subpopulation of human glioma associated macrophages linked to glioma progression. Cancer cell, 44(1), 129.

Yamamoto N, et al. (2025) HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(4), 733.

Carneiro BA, et al. (2025) Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors. Cancer research communications, 5(3), 444.

Gobbini E, et al. (2025) The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with Melanoma. Cancer immunology research, 13(4), 517.

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer cell, 43(2), 269.

Huyghe N, et al. (2025) Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan. Cell reports. Medicine, 6(7), 102201.

Suzuki H, et al. (2025) GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression. Cancer research communications, 5(9), 1530.

Stockem CF, et al. (2025) Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(18), 3897.

Damle SR, et al. (2025) Intratumoral three-cell-type clusters are a conserved feature of endogenous antitumor immunity. *Cancer immunology research*.

Quandt Z, et al. (2025) Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas. *Journal for immunotherapy of cancer*, 13(8).

Papadopoulou C, et al. (2025) Protocol to investigate fibroblastic reticular cell-immune cell interaction in human lung cancer. *STAR protocols*, 6(4), 104256.

Li H, et al. (2025) Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. *Cell reports. Medicine*, 6(2), 101927.

Wu SG, et al. (2025) Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis. *Clinical and translational medicine*, 15(1), e70149.

Alcindor T, et al. (2025) Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: The role of M2 macrophage landscape in predicting response. *Cell reports. Medicine*, 6(4), 102045.

Bechter O, et al. (2025) A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(12), 2358.

Stupichev D, et al. (2025) AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma. *Cell reports. Medicine*, 6(8), 102299.

Chaudhary R, et al. (2025) Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*.

Cakmak P, et al. (2025) Spatial immune profiling defines a subset of human gliomas with functional tertiary lymphoid structures. *Immunity*, 58(11), 2847.

Kouzu K, et al. (2025) AI-driven spatial mapping of myxoid stroma and tumor-infiltrating lymphocytes in esophageal squamous cell carcinoma. *Esophagus : official journal of the Japan Esophageal Society*.

Chelushkin MA, et al. (2024) Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(18), 4227.